BioSpace News Archive

A recent report by Transparency Market Research states that global wearable medical devices market is projected to witness a substantial growth.

According to the report, the global orthopedic biomaterials market was valued at US$ 11.3 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027. Rise in percentage of population requiring orthopedic implants, and increase in incidence rate of injuries related to accidents, sports, and adventure are anticipated to augment the global orthopedic biomaterials market from 2019 to 2027.

Transparency Market Research has published a new report titled “Gene Delivery System Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

Brain hemorrhage, also called brain bleed, is a type of stroke, wherein bleeding happens in the brain.

The prevalence of behavioral health disorders has increased in the past few years, owing to which, TMR analysts hold a positive perspective of the market.

Transparency Market Research has published a new report titled, ‘Antimicrobial Susceptibility Test Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Analysis of genes is the strategy for research and development in the fields of genetics and molecular biology.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23. Sunesis expects to receive gross proceeds of approximately $12 million from this offering, before deducting the underwriting discounts and estimated offering expenses. Sunesis has granted the underwriters a 30-day opti

- Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period - Trial also demonstrates statistically significant improvements in all six secondary endpoints in the 30 mg and 60 mg once-daily treatment arms - Data from this trial and previous Phase 2/3 trial will be the basis for regulatory submissions in the

Today, Feelmore Labs, an innovative wellness technology company driven by neuroscience, unveiled its inaugural product: Cove, a new wearable consumer device that is scientifically proven to effortlessly reduce stress and improve sleep.